Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 004468500 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
TPG GP A, LLC
13D
|
12.6% |
4/24/2026
Event 4/17/2025
|
||
| TPG GP A, LLC | 12.6% | |||
| James G. Coulter | 12.6% | |||
| Jon Winkelried | 12.6% | |||
|
venBio Global Strategic Fund V, L.P.
13D
|
10.0% |
4/27/2026
Event 4/15/2026
|
||
| venBio Global Strategic Fund V, L.P. | 10.0% | |||
| venBio Global Strategic GP V, LLC | 10.0% | |||
|
Logos Global Management LP
13G
|
10.0% |
8/17/2026
Event 5/11/2026
|
||
| Logos Global Management LP | 10.0% | |||
| Logos Global Management GP LLC | 10.0% | |||
| Logos Global Master Fund LP | 5.1% | |||
| Logos GP LLC | 5.1% | |||
| Logos Opportunities Fund V LP | 5.0% | |||
| Logos Opportunities V GP LLC | 5.0% | |||
| Arsani William | 10.0% | |||
| Graham Walmsley | 5.0% | |||
|
Paradigm Biocapital Advisors LP
13G
|
9.2% |
4/24/2026
Event 4/17/2026
|
||
| Paradigm BioCapital Advisors LP | 9.2% | |||
| Paradigm BioCapital Advisors GP LLC | 9.2% | |||
| Senai Asefaw, M.D. | 9.2% | |||
| Paradigm BioCapital International Fund Ltd. | 8.1% | |||
|
Franklin Resources, Inc.
13G/A
|
8.3% |
7/28/2026
Event 6/30/2026
|
||
| Franklin Resources, Inc. | 8.3% | |||
| Charles B. Johnson | 0% | |||
| Rupert H. Johnson, Jr. | 0% | |||
| Franklin Advisers, Inc. | 8.3% | |||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
6.5% |
4/24/2026
Event 4/17/2026
|
||
| Frazier Life Sciences Public Fund, L.P. | 6.5% | |||
| FHMLSP, L.P. | 6.5% | |||
| FHMLSP, L.L.C. | 6.5% | |||
| Frazier Life Sciences XI, L.P. | 0.1% | |||
| FHMLS XI, L.P. | 0.1% | |||
| FHMLS XI, L.L.C. | 0.1% | |||
| Frazier Life Sciences XII, L.P. | 0.8% | |||
| FHMLS XII, L.P. | 0.8% | |||
| FHMLS XII, L.L.C. | 0.8% | |||
|
Alyeska Investment Group, L.P.
13G/A
|
5.6% |
11/14/2025
Event 9/30/2025
|
||
| Alyeska Investment Group, L.P. | 5.6% | |||
| Alyeska Fund GP, LLC | 5.6% | |||
| Anand Parekh | 5.6% | |||
| Janus Henderson Group Ltd. 13G | 5.4% |
8/13/2026
Event 6/30/2026
|
||
|
Venrock Healthcare Capital Partners III, L.P.
13G
|
5.2% |
4/24/2026
Event 4/17/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 5.2% | |||
| VHCP Co-Investment Holdings III, LLC | 5.2% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 5.2% | |||
| VHCP Management III, LLC | 5.2% | |||
| VHCP Management EG, LLC | 5.2% | |||
| Nimish Shah | 5.2% | |||
| Bong Y. Koh | 5.2% | |||
| BlackRock, Inc. 13G | 5.1% |
7/27/2026
Event 6/30/2026
|
||
|
Vivo Opportunity Fund Holdings, L.P.
13G
|
5.0% |
7/8/2026
Event 7/6/2026
|
||
| Vivo Opportunity Fund Holdings, L.P. | 1.8% | |||
| Vivo Opportunity Co-Invest, L.P. | 1.2% | |||
| Vivo Opportunity Co-Invest (Cycle 3), L.P. | 2.0% | |||
| Vivo Opportunity, LLC | 5.0% | |||
| Vivo Opportunity Cayman Fund, L.P. | 0.2% | |||
| Vivo Opportunity Cayman, LLC | 0.2% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (2) | ||||
| Vanguard Group Inc 13G/A | 4.95% |
4/30/2025
Event 3/31/2025
|
||
|
Contrarian Alpha, LP
13G/A
|
4.9% |
11/14/2025
Event 9/30/2025
|
||
| Contrarian Alpha, LP | 1.1% | |||
| Contrarian Achieve SPV, LP | 3.8% | |||
| Contrarian Achieve GP LLC | 3.8% | |||
| Contrarian Alpha GP, LLC | 1.1% | |||
| Contrarian Alpha Management, LLC | 1.1% | |||
| Parker Quillen | 4.9% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 10 | 268 k | $2.11 M |
| 2026 Q2 | 119 | 82.7 M | $541 M |
| 2026 Q1 | 87 | 21.5 M | $63.6 M |
| 2025 Q4 | 83 | 23.2 M | $115 M |
| 2025 Q3 | 73 | 15.5 M | $48.9 M |
| 2025 Q2 | 71 | 26.4 M | $59.6 M |
| 2025 Q1 | 76 | 14.4 M | $38.4 M |
| 2024 Q4 | 74 | 16.3 M | $57.5 M |
| 2024 Q3 | 70 | 16.9 M | $81.2 M |
| 2024 Q2 | 65 | 19.3 M | $81.7 M |
| 2024 Q1 | 46 | 16.5 M | $64.9 M |
| 2023 Q4 | 33 | 2.73 M | $11.2 M |
| 2023 Q3 | 40 | 3.12 M | $13.4 M |
| 2023 Q2 | 48 | 3.57 M | $18.6 M |
| 2023 Q1 | 40 | 2.47 M | $16.6 M |
| 2022 Q4 | 33 | 2.02 M | $4.96 M |
| 2022 Q3 | 29 | 2.12 M | $7.00 M |
| 2022 Q2 | 34 | 2.04 M | $9.97 M |
| 2022 Q1 | 39 | 1.93 M | $14.6 M |
| 2021 Q4 | 33 | 2.02 M | $15.7 M |
| 2021 Q3 | 33 | 1.78 M | $15.2 M |
| 2021 Q2 | 30 | 1.95 M | $17.5 M |
| 2021 Q1 | 17 | 1.01 M | $11.7 M |
| 2020 Q4 | 18 | 504 k | $4.08 M |
| 2020 Q3 | 14 | 453 k | $3.79 M |